Results 91 to 100 of about 15,674 (165)
Cancer Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin +6 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.Lysine lactylation (Kla) serves as a metabolic–epigenetic switch governed by writer–eraser–reader regulatory systems, directly connecting the Warburg effect to diverse forms of tumour drug resistance. Intratumoural lactylation critically contributes to treatment failure in chemotherapy, targeted therapy and immunotherapy.
Juan Li +5 more
wiley +1 more source
Vacuolization as a Novel Approach to Cancer Therapy
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.This review discusses the novel strategy of inducing vacuole formation in cancer cells using small molecules, that induce nonapoptotic cell death mechanisms, such as paraptosis, oncosis, autophagy, and methuosis, and its potential in overcoming resistance to apoptosis‐based cancer therapies.
Mariah Pasternak +9 more
wiley +1 more source
Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.ABSTRACT Background Sarcopenia has emerged as a potential prognostic factor in patients with advanced prostate cancer (PCa), requiring interventions for its prevention and treatment. Objective We aimed to systematically identify, critically assess and synthesize the available evidence on the effectiveness and safety of interventions for preventing or ...
Pedro de Pablos‐Rodríguez +8 more
wiley +1 more source
Molecular Carcinogenesis, Volume 65, Issue 6, Page 665-676, June 2026.ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer‐related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one‐third of patients develop biochemical recurrence within 10 years. Although prostate‐specific
Juliana Ramos Chaves +7 more
wiley +1 more source
Restoration of Immune Surveillance in Prostate Cancer Prevention by Sulforaphane in Hi‐Myc Mice
Molecular Carcinogenesis, Volume 65, Issue 6, Page 677-686, June 2026.ABSTRACT Oral administration of broccoli constituent sulforaphane (SFN) prevents prostate cancer development in preclinical mouse models. However, the mechanism(s) underlying prostate cancer prevention by SFN are not fully understood. In this study, we used a human relevant mouse model (Hi‐Myc mice) to demonstrate restoration of immune surveillance by ...
Krishna B. Singh +3 more
wiley +1 more source
Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application
MedComm, Volume 7, Issue 6, June 2026.The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang +12 more
wiley +1 more source
MedComm, Volume 7, Issue 6, June 2026.Leveraging integrated single‐cell and spatial transcriptomics, we delineated the sustained immunosuppressive landscape during prostate disease progression. Based on this, we have developed a precise gene‐based diagnostic classifier and a multimodal prognostic model.
Yuanyuan Luo +18 more
wiley +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview
MedComm, Volume 7, Issue 6, June 2026.The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele +7 more
wiley +1 more source
Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation
MedComm – Oncology, Volume 5, Issue 2, June 2026.The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong +4 more
wiley +1 more source